Time: 14:00 - 15:30 UK Time
Presenters: Kim Cocks (Adelphi Values), Andrew Thompson (EMA) and Christoph Gerlinger (Bayer)
Clinical Trials are increasingly featuring a wide variety of Patient Reported Outcomes (PROs). PROs are important endpoints to both regulatory and health technology bodies in their assessments and approvals. There are standard ways in which PRO instruments are developed and validated, as well as important concepts for designing and interpretation of PRO data in clinical trials such as assessing the Minimally Clinically Important Differences (MCIDs/MIDs) and the use of a Responder definition.
The intent of this webinar is to describe an overview of how PROs tools are developed and used in clinical trial settings and how results can be clinically and meaningfully interpreted. In addition, a regulatory viewpoint will be shared on the key considerations for PROs. The talks will also include examples and case-studies showing the derivation of a validated thresholds for treatment responder and interpretation of PROs in the context of regulatory approval.
Click here to view the flyer.Kim Cocks (Adelphi Values)
Kim Cocks is a Director and Principal Statistician at Adelphi Values, a global healthcare consultancy. She has worked as a medical statistician and clinical trial methodologist for over 20 years across pharmaceutical, academic and consultancy environments. She specialises in PRO interpretation and analysis and is an active member of both the EORTC Quality of Life group and ISOQOL.PROs are validated instruments designed to provide a direct report from the patient on aspects of their health including symptoms and functioning. This talk will provide a brief overview of how PROs are developed, how they provide a score for multi-dimensional aspects of a patient’s health and why these can be difficult to interpret. The variety of quantitative and qualitative methods available to aid interpretation will be introduced.
Andrew Thomson (EMA)
Andrew Thomson is a statistician at the EMA, in the Human Medicines Research & Development Support Division. Prior to joining the EMA in 2014, he spent 7 years at the MHRA, initially as a Statistical Assessor in the Licensing Division, and subsequently Head of Epidemiology in the Vigilance & Risk Management of Medicines Division.
Abstract
Regulatory Considerations for PROs
In this talk I will present some regulatory considerations on the use of PROs in regulatory assessment, and how they can be developed. These will be discussed alongside a recent case example that has been through the qualification procedure at EMA.
Christoph Gerlinger (Bayer)
Christoph Gerlinger is Bayer’s Expert Statistician for Health Technology Assessment and Women’s Health. He is the regulatory chair of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and a work package leader for the IMI BigData@Heart project. Christoph worked as statistician over 25 years in the pharmaceutical industry and in his spare time he teaches at the University Medical School of Saarland.
Abstract
Empirical derivation of the minimal important difference for PROs
In this talk I will present some methods on how to derive the minimal important difference for PROs from a clinical trial. I will present a worked example where we used this empirical minimal important difference to formulate a responder definition that was then accepted by the FDA.
| Registration | |
| PSI Member | Free |
| Non-member | £20 (plus VAT) |
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Whatever your current challenge(s) at work, this workshop will explore what's holding you back, and how barriers can be removed in order to progress and achieve.
A PSI Training Course covering the statistical methods for repeated measures and other clustered data. Course will cover: Conditional models for continuous hierarchical data, Conditional models for continuous longitudinal data, Marginal models (GEE) for continuous longitudinal data & Discrete data.
We’re now searching at all levels for Biostatisticians and Statistical Programmers to join our International BARDS Health Technology Assessment team at our London and Zurich hubs.
The Associate Director of Biostatistics is the key client interface for all statistical issues and discussions.
In this role you will consult in the design of complex and innovative studies and clinical trial programs as well as Leading DMC/DSMB processes.
This is an excellent opportunity for someone that loves working directly with clients, contributing as a high-level project lead and key contributor.
Join our growing team and discover your extraordinary potential by working as a Covance by Labcorp Biostatistician 2 within our early phase biostatistics department.
The opportunity to combine an exciting professional career with excellent quality of life in the Cairngorms National Park area of Scotland.
Join our growing team and discover your extraordinary potential by working as a Covance by Labcorp Principal Biostatistician.
As a seasoned Biostatistician, will work primarily on Immunology: GI and Dermatology trials with a focus on Late Phase studies. Some PK Analysis experience highly desired.
As a seasoned Biostatistician, will work primarily in late phase oncology.
As an experienced pharmaceutical statistician, you will support Cytel and a client of our Functional Service Provider (FSP) division.
As a Sr Bios, you will function independently as Lead Statistician on projects and support/project statistician on others.
The Senior Manager Biostatistics will be responsible for leading biostatistics strategy and activities for a compound and/or for individual clinical studies.
As a Sr Mgr, Biostatistics you will manage a team of Statisticians and Programmers within the FSP department, as well as managing project work.
At its core, the role of a Senior Statistician at Veramed is to provide statistical support to the statistics and programming department across a range of projects, clients and therapeutic areas.
As a Senior or Principal Biotatistician, you will hold a combined project leadership and hands-on technical statistics role, working across a range of phases and therapeutic areas.
You will participate in the development of study protocols including participation in study design discussions and sample size calculations, and review CRFs and data review guidelines.
As a Senior or Principal Statistician, you will hold a combined project leadership and hands-on technical statistics role., working across a range of phases and therapeutic areas.
We are looking for passionate and motivated statisticians to work within our Services team to deliver high quality, innovative, analytical services within a clinical setting as our KerusCloud platform moves into the next phase.
Would you like to join a dynamic, growing firm where you can really make an impact, not just on the company but to accelerate drug development and ultimately benefit patients?
Opportunity to join Amgen's centre for design & analysis. We are looking for a talented Statistician to join the Global Biostatistical Science team.
